On October 30, the DEA announced that Insys Therapeutics applied to manufacture marijuana and THC for distribution.
In 2016, Insys Therapeutics donated $500,000 to help defeat Prop 205, a recreational marijuana initiative in Arizona, Filter reports. Then, in 2017, Insys received FDA approval to distribute Syndros, their synthetic form of THC.
The DEA posted online that: “The company plans to manufacture bulk synthetic active pharmaceutical ingredients (APIs) for product development and distribution to its customers. No other activity for these drug codes are authorized for this registration.”
The DEA’s online document has a comment period that ends on Dec 31, 2018.
Photo: Glassdoor (goo.gl/ybKPnN)